Notice: This company has been marked as potentially delisted and may not be actively trading. Yumanity Therapeutics (YMTX) News Today Add Compare Share Share Headlines Stock AnalysisInsider TradesTrends All Sources Trusted Sources MarketBeat Benzinga Bloomberg GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 May 2022 April 2022 March 2022 February 2022 Time Period JSPR Jasper Therapeutics, Inc.March 20, 2024 | seekingalpha.comCara Therapeutics Inc CARANovember 3, 2023 | morningstar.comYumanity Therapeutics Inc.October 6, 2023 | thestreet.comFormer Onyx CEO Returns to Biotech to Launch Boston Start UpJuly 5, 2023 | thestreet.comKineta raises $6M through registered direct offeringMay 1, 2023 | bizjournals.comColorectal Cancer Therapeutics Market Size to Surpass US$ 24.58 Billion by 2030 - Growth Plus ReportsFebruary 22, 2023 | finance.yahoo.comYumanity Therapeutics's Return On Capital Employed InsightsDecember 26, 2022 | msn.comKineta finalizes reverse merger with Yumanity, secures additional fundingDecember 20, 2022 | bizjournals.comYumanity Therapeutics Declares Special Dividend In Connection with Proposed Asset Sale to Janssen and Merger with KinetaDecember 5, 2022 | finance.yahoo.comWhy Is Yumanity Therapeutics (YMTX) Stock Up Today?December 5, 2022 | investorplace.comYumanity Therapeutics Inc: Yumanity Therapeutics Reports Third Quarter 2022 Financial Results and Recent Corporate DevelopmentsNovember 14, 2022 | finanznachrichten.deYumanity Therapeutics Reports Third Quarter 2022 Financial Results and Recent Corporate DevelopmentsNovember 14, 2022 | finance.yahoo.comYumanity Therapeutics Announces Effectiveness of Registration Statement on Form S-4 In Connection With Proposed Asset Sale to Janssen and Merger with Kineta, Inc.November 10, 2022 | finance.yahoo.comYumanity Therapeutics Announces Filing of Registration Statement on Form S-4 In Connection With Proposed Asset Sale to Janssen and Merger with KinetaAugust 29, 2022 | finance.yahoo.comYumanity Therapeutics Reports Second Quarter 2022 Financial Results and Recent Corporate DevelopmentsAugust 4, 2022 | finance.yahoo.comInside Kineta's plans after unveiling reverse merger dealJune 8, 2022 | finance.yahoo.comSeattle biotech Kineta to go public in merger deal with Yumanity TherapeuticsJune 7, 2022 | bizjournals.comShort Volatility Alert: Yumanity Therapeutics, Inc.June 7, 2022 | msn.comYumanity to Sell Neurosciences Candidates, Merge With Kineta >YMTXJune 6, 2022 | marketwatch.comYumanity stock soars 46% on all-stock merger with Kineta; lead product sale to J&J for $26MJune 6, 2022 | seekingalpha.comYumanity Therapeutics To Sell 2 Product Candidates For $26 Mln In Cash; Inks Merger Deal With KinetaJune 6, 2022 | nasdaq.comYumanity Therapeutics Shares Trading Higher Today - Read Here WhyJune 6, 2022 | finance.yahoo.comWhy Is Yumanity Therapeutics (YMTX) Stock Up 50% Today?June 6, 2022 | investorplace.comYumanity Therapeutics Announces Definitive Agreements for Two Strategic TransactionsJune 6, 2022 | finance.yahoo.com53 Stocks Moving In Thursday's Mid-Day SessionJune 2, 2022 | benzinga.comYumanity Therapeutics GAAP EPS of -$1.24, revenue of $1.02MMay 14, 2022 | seekingalpha.comYumanity Therapeutics (YMTX) Reports Q1 Loss, Misses Revenue EstimatesMay 13, 2022 | finance.yahoo.comYumanity Therapeutics Reports First Quarter 2022 Financial Results and Recent Corporate DevelopmentsMay 13, 2022 | finance.yahoo.comLooking Into Yumanity Therapeutics's Return On Capital EmployedMarch 25, 2022 | benzinga.comYumanity Therapeutics GAAP EPS of -$3.84, revenue of $8.04MMarch 24, 2022 | seekingalpha.comYumanity Therapeutics Reports Full-Year 2021 Financial Results and Recent Corporate DevelopmentsMarch 24, 2022 | finance.yahoo.comYumanity to cut 60% of workforce as it evaluates strategic alternativesFebruary 17, 2022 | seekingalpha.comYumanity Therapeutics Exploring Strategic Alternatives to Enhance Shareholder Value and Announces RestructuringFebruary 17, 2022 | finance.yahoo.comTrading was temporarily halted for "YMTX" at 08:02 AM with a stated reason of "News pending."February 17, 2022 | marketbeat.comYumanity Says FDA Puts Partial Hold on YTX-7739 Studies >YMTXJanuary 19, 2022 | marketwatch.comYumanity Therapeutics Shares Tumble on Partial FDA Study Hold >YMTXJanuary 19, 2022 | marketwatch.comYumanity's multi-dose clinical trial put on hold by FDA, stock slides 12%January 19, 2022 | seekingalpha.comYumanity Shares Fall On FDA Hold On Multidose Trials In Parkinson's DiseaseJanuary 19, 2022 | msn.comYumanity Reports Partial Clinical Hold by U.S. FDA on Multidose Clinical Trials for YTX-7739January 19, 2022 | finance.yahoo.comYumanity Therapeutics (NASDAQ:YMTX) Upgraded to "Buy" by Zacks Investment ResearchZacks Investment Research upgraded Yumanity Therapeutics from a "hold" rating to a "buy" rating and set a $3.00 price target for the company in a research report on Tuesday.January 18, 2022 | marketbeat.comYumanity’s Approach to Neurodegenerative Diseases Validated by Two External CollaborationsJanuary 11, 2022 | finance.yahoo.comYumanity Therapeutics, Inc. (NASDAQ:YMTX) Short Interest Down 61.4% in DecemberYumanity Therapeutics, Inc. (NASDAQ:YMTX) was the target of a significant drop in short interest in December. As of December 15th, there was short interest totalling 61,200 shares, a drop of 61.4% from the November 30th total of 158,400 shares. Based on an average daily trading volume, of 175,700 shares, the days-to-cover ratio is presently 0.3 days. Approximately 0.9% of the shares of the stock are sold short.January 5, 2022 | marketbeat.comYumanity Therapeutics to Present at the H.C. Wainwright BioConnect ConferenceJanuary 4, 2022 | finance.yahoo.comYumanity Therapeutics, Inc. (YMTX)December 31, 2021 | realmoney.thestreet.comYumanity Therapeutics Inc Shares Fall 0.7% Below Previous 52-Week Low - Market MoverDecember 29, 2021 | nasdaq.comYumanity Therapeutics to Present at Multiple Upcoming November Investor ConferencesNovember 16, 2021 | finance.yahoo.comYumanity: Q3 Earnings SnapshotNovember 15, 2021 | chron.comYumanity Therapeutics Reports Third Quarter 2021 Financial Results and Recent Corporate DevelopmentsNovember 15, 2021 | finance.yahoo.comMid-afternoon market update: Nasdaq tumbles 300 points, Pubmatic shares gain after Q3 resultsNovember 12, 2021 | fxstreet.comYumanity Therapeutics Stock Plunges After Parkinson's Trial DataNovember 11, 2021 | finance.yahoo.com Get Yumanity Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for YMTX and its competitors with MarketBeat's FREE daily newsletter. Email Address YMTX Media Mentions By Week YMTX Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. YMTX News Sentiment▼0.000.74▲Average Medical News Sentiment YMTX News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. YMTX Articles This Week▼00▲YMTX Articles Average Week Get Yumanity Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for YMTX and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies ProMIS Neurosciences News Coeptis Therapeutics News Daré Bioscience News iBio News CytoMed Therapeutics News DURECT News Natural Alternatives International News Citius Pharmaceuticals News Traws Pharma News Lakeshore Biopharma News Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:YMTX) was last updated on 1/30/2025 by MarketBeat.com Staff From Our PartnersTexas approves new currencyRural Texas Town Ramps Up Global Currency War A small town has joined a radical $1.9 trillion attack on the...Stansberry Research | SponsoredIs Big Tech dead?China just threw a “$5.5 million” curveball called Deep Seek to Silicon Valley and the timing of it is no coin...Brownstone Research | SponsoredTrillion-Dollar Crypto PlayPotential $20-trillion opportunity? Put $500 into THIS AI Coin for 2025… Crypto 101 Media | SponsoredTrump’s back in the oval office. Buy this coin now.Juan Villaverde called the top and bottom of every crypto bull market since 2012. And he says 2025 could be...Weiss Ratings | SponsoredHas Trump finally met his match?Dylan Jovine predicted the 2008 crash over a year before it happened. Folks who listened to him had the chance...Behind the Markets | SponsoredI was wrong. Dead wrong. I thought what happened 25 years ago was a once- in-a-lifetime event… but how wrong I was. Because here we...Porter & Company | SponsoredURGENT: This Altcoin Opportunity Won’t Wait – Act NowCrypto has officially entered the "banana zone" – that wild phase where prices can 1000x in days. It happen...Crypto Swap Profits | SponsoredAlert: DOGE goes live"It's Elon's world, and the rest of us live in it." Every investor in America is trying to figure out what ...Altimetry | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Yumanity Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Yumanity Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
